Hydromorphon Painbreak Pb Pharma Gmbh (Hydromorphone Hydrochloride)

Hydromorphone is used in the management of pain conditions that require strong opioid therapy.

• Acute postoperative pain: provides rapid relief of severe pain following surgery.
• Cancer‑related pain: controls moderate to severe pain associated with malignant disease.
• Severe chronic non‑cancer pain: offers long‑term analgesia when other treatments are inadequate.
• Palliative care pain: alleviates distressing pain in end‑of‑life settings.

• Hydromorphone acts as a high‑affinity agonist at the μ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces neuronal excitability, and decreases the release of nociceptive neurotransmitters such as substance P and glutamate. The resulting modulation of pain pathways produces potent analgesia and also induces sedation and respiratory depression at higher doses.

Hydromorphone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea
• Constipation
• Drowsiness
• Dizziness
• Dry mouth
• Sweating

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Bradycardia
• Allergic reactions (rash, pruritus, anaphylaxis)
• Withdrawal symptoms on abrupt discontinuation
• Dependence or abuse potential

When prescribing hydromorphone, clinicians should observe several safety precautions to minimize risks.

• Assess pain severity and prior opioid use: confirm indication and evaluate opioid tolerance.
• Evaluate respiratory function: avoid use in patients with compromised ventilation.
• Monitor for sedation and CNS depression: advise patients not to operate machinery while impaired.
• Use caution in renal or hepatic impairment: dose adjustments may be required.
• Review concomitant medications: avoid combinations that increase CNS depression.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Hydromorphone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression.
• MAO inhibitors or within 14 days of discontinuation: can cause severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Anticholinergic agents: may exacerbate constipation.
• Drugs that prolong QT interval: may increase risk of cardiac arrhythmias.